TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9625042

Group type: EXPERIMENTAL
Intervention: Sodium dodecyl sulfate‐agarose gel electrophoresis (SDS‐AGE)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine agarose gel electrophoresis (AGE)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Immunofixation
Number of subjects: 47
Study: 8706062

Group type: EXPERIMENTAL
Intervention: Nitroglycerine infusion
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2512162

Group type: EXPERIMENTAL
Intervention: Intermittent administration of NTG 20 mg (24 h)‐1 patches with a 12-hour nitrate-free interval
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous treatment with NTG 20 mg (24 h)‐1 patches
Number of subjects: 10
Study: 5035

Group type: EXPERIMENTAL
Intervention: Chlorprothixene-Dextromoramide Neurolept-Analgesia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Alfadione-Fentanyl Venous Anesthesia
Number of subjects: 14
Study: 31104476

Group type: EXPERIMENTAL
Intervention: homeCIMT
Number of subjects: 22
Study: 28712181

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extra virgin olive oil (EVOO) 2 tablespoons orally per day
Number of subjects: 60
Study: 26495916

Group type: EXPERIMENTAL
Intervention: CHO‐loading (400 ml Nutricia pre‐op®) 2 hours prior to surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (clear water)
Number of subjects: 40
Study: 23566997

Group type: EXPERIMENTAL
Intervention: OneTouch® Verio™Pro+ BG meter
Number of subjects: 566
Study: 22094481

Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling (ASL) MRI
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 34

Group type: COMPARATOR
Intervention: ASL and FDG-PET
Number of subjects: 34
Study: 19919976

Group type: EXPERIMENTAL
Intervention: SLV320 10 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: SLV320 15 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 111
Study: 16798663

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Combination treatment (Simvastatin + Celiprolol)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 112
Study: 14747191

Group type: EXPERIMENTAL
Intervention: Breastfeeding compounds
Number of subjects: 47

Group type: COMPARATOR
Intervention: Carrier control
Number of subjects: 47
Study: 11031342

Group type: EXPERIMENTAL
Intervention: Macrolide antibiotic treatment (n = 11)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment (n = 7)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Asthmatic subjects with M pneumoniae
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 28
Study: 9347661

Group type: EXPERIMENTAL
Intervention: Cuprophane (CUP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cellulose diacetate (CD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polysulphone (PS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (PAN)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (normal controls)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Predialysis ESRD patients
Number of subjects: 9
Study: 8094995

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3538922

Group type: EXPERIMENTAL
Intervention: Thai Government Pharmaceutical Organization (GPO) antivenom
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Twyford Pharmaceutical antivenom
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Thai Red Cross (TRC) antivenom
Number of subjects: 46

Group type: COMPARATOR
Intervention: TRC antivenom
Number of subjects: 46

Group type: COMPARATOR
Intervention: GPO antivenom
Number of subjects: 46

Group type: COMPARATOR
Intervention: Twyford antivenom
Number of subjects: 46
Study: 30086656

Group type: COMPARATOR
Intervention: Wealth group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Charity group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health group
Number of subjects: 0
Study: 27231160

Group type: EXPERIMENTAL
Intervention: Stents-combination (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stent-graft (Group II)
Number of subjects: 50
Study: 24731537

Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) tool assessments
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Recommendations for improvements to the RoB tool
Number of subjects: 380
Study: 22635965

Group type: EXPERIMENTAL
Intervention: Antegrade autologous priming (AAP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (without AAP)
Number of subjects: 72
Study: 20152214

Group type: EXPERIMENTAL
Intervention: New strategy combining clinical risk score and NT‐proBNP without exercise testing
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual management involving exercise testing
Number of subjects: 320
Study: 18662172

Group type: EXPERIMENTAL
Intervention: Daptomycin at 10 mg/kg every 24 h for 4 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care therapy with vancomycin or semi-synthetic penicillin
Number of subjects: 100
Study: 15920983

Group type: EXPERIMENTAL
Intervention: ADAC Pinnacle system
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nomos Corvus system
Number of subjects: 14
Study: 11830808

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency probe at nonablative energy levels
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mechanical shaver
Number of subjects: 39
Study: 10500534

Group type: EXPERIMENTAL
Intervention: University hospitals
Number of subjects: 1083

Group type: COMPARATOR
Intervention: General hospitals
Number of subjects: 1083
Study: 7568861

Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2209033

Group type: EXPERIMENTAL
Intervention: No weekly change (NWC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Guidewire exchange (GWX)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Percutaneous (PERC)
Number of subjects: 112
Study: 398660

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31865282

Group type: EXPERIMENTAL
Intervention: Scalp Cooling (SC)
Number of subjects: 51
Study: 31132302

Group type: EXPERIMENTAL
Intervention: Mindfulness module of dialectical behavioural therapy (DBT‐M)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Interpersonal effectiveness module (DBT‐IE)
Number of subjects: 65
Study: 28151944

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (20 participants)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal sleep (20 participants)
Number of subjects: 40
Study: 25884980

Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri SBT2055 (LG2055) in fermented milk (FM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (FM without LG2055)
Number of subjects: 0
Study: 23672520

Group type: EXPERIMENTAL
Intervention: Home-based pelvic floor muscle training (PFMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (written training instructions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 100
Study: 21836158

Group type: EXPERIMENTAL
Intervention: Modal alerts
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-modal alerts
Number of subjects: 24

Group type: COMPARATOR
Intervention: No alert
Number of subjects: 24
Study: 19423110

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 17234318

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 12
Study: 14998589

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (smoking cessation, exercise training, nutritional aspects, self-management programs)
Number of subjects: 0
Study: 11429362

Group type: EXPERIMENTAL
Intervention: Single injection technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple injection technique
Number of subjects: 50
Study: 9894701

Group type: EXPERIMENTAL
Intervention: Naloxone (0.02 mg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Head-up tilt test
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Isoproterenol test
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Passive negative tilt test
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Negative isoproterenol tilt test
Number of subjects: 35
Study: 7994448

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg oid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2680083

Group type: EXPERIMENTAL
Intervention: 75 mg of phenylpropanolamine HCl (PPA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 5551272

Group type: EXPERIMENTAL
Intervention: Oral iron 30 mg once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral iron 60 mg once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral iron 120 mg once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Parenteral iron 1 g followed by oral iron 60 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Demonstrable iron stores
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lack of demonstrable iron at 37th week
Number of subjects: 5
Study: 31735256

Group type: EXPERIMENTAL
Intervention: Mixed-contrast training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fixed-contrast training
Number of subjects: 19
Study: 29677345

Group type: EXPERIMENTAL
Intervention: 60-mg caffeine group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 120-mg caffeine group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 180-mg caffeine group
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0-mg group (control)
Number of subjects: 33
Study: 28643901

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1000 mg iron)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 26683949

Group type: EXPERIMENTAL
Intervention: DAPT + atorvastatin 20 mg daily + lansoprazole 30 mg daily (Group A)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: DAPT + atorvastatin 20 mg daily (Group B)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: DAPT + lansoprazole 30 mg daily (Group C)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 104
Study: 22750085

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 20843556

Group type: EXPERIMENTAL
Intervention: lithium (1‐1.2 mEq/L) + tamoxifen 80 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: lithium (1‐1.2 mEq/L) + placebo
Number of subjects: 40
Study: 18939399

Group type: EXPERIMENTAL
Intervention: Intravenous Tramadol (100 mg) and IV hyoscine N butylbromide (20 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: IV hyoscine N butylbromide (20 mg) only
Number of subjects: 84
Study: 15825976

Group type: EXPERIMENTAL
Intervention: Cultural characteristics identified through focus group discussions
Number of subjects: 26
Study: 12538307

Group type: EXPERIMENTAL
Intervention: Behavioural programme
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 316

Group type: COMPARATOR
Intervention: High number of feeds (>11) in 24 hours
Number of subjects: 316
Study: 10659801

Group type: EXPERIMENTAL
Intervention: 6-month aerobic training program
Number of subjects: 18
Study: 8885906

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg) and medroxyprogesterone (10 mg) cyclically for 3 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 83
Study: 1520045

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily for 6 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily for 6 weeks
Number of subjects: 17
Study: 6500763

Group type: EXPERIMENTAL
Intervention: Isofezolac (50 mg) alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isofezolac (50 mg) with aspirin (1 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isofezolac (50 mg) with phosphalugel (11 g aluminum phosphate)
Number of subjects: 6
Study: 30895459

Group type: EXPERIMENTAL
Intervention: Suspension with prior climbing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suspension without prior climbing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-suspension recovery
Number of subjects: 20
Study: 30187789

Group type: EXPERIMENTAL
Intervention: Flexima® Active O Convex
Number of subjects: 40
Study: 26768572

Group type: EXPERIMENTAL
Intervention: Ebola vaccine intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study: 24798153

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uric acid plus method (ascorbate oxidase assay)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uric acid method (non‐ascorbate oxidase assay)
Number of subjects: 40
Study: 22569288

Group type: EXPERIMENTAL
Intervention: Daily atorvastatin (QD)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Alternate-day atorvastatin (QOD)
Number of subjects: 300
Study: 20437055

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 45
Study: 17509688

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15%
Number of subjects: 163

Group type: COMPARATOR
Intervention: Brinzolamide 1%
Number of subjects: 163
Study: 17224714

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 9
Study: 12910715

Group type: EXPERIMENTAL
Intervention: KC-404 sustained release tablets (20 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: KC-404 capsules (20 mg)
Number of subjects: 19
Study: 10839227

Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) performing 36 maximal isokinetic eccentric contractions of the elbow flexors (ECC1) followed by a repeated bout (ECC2) two days later
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON) performing 36 maximal isokinetic eccentric contractions of the elbow flexors (ECC1)
Number of subjects: 20
Study: 9352730

Group type: EXPERIMENTAL
Intervention: H. pylori seropositive children (n=87)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Age-matched control group (n=50)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Seropositive children with recent upper gastrointestinal bleeding (n=8)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Anthropometric data from institutionalised children
Number of subjects: 157
Study: 8254651

Group type: EXPERIMENTAL
Intervention: MMPI cluster group membership
Number of subjects: 517
Study: 3924221

Group type: EXPERIMENTAL
Intervention: Physiotherapy (postural drainage, external help with breathing, percussion, and vibration)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (advice on expectoration, deep breathing, and how to exercise to avoid thrombosis)
Number of subjects: 171
Study: 30627850

Group type: EXPERIMENTAL
Intervention: CARE + Corrections (computerized counseling session plus post‐incarceration text messaging intervention)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 110
Study: 28816883

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg IV atropine
Number of subjects: 41

Group type: COMPARATOR
Intervention: No atropine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Systemic desaturation
Number of subjects: 41
Study: 26132827

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body mass)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 28
Study: 25041870

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 22595327

Group type: EXPERIMENTAL
Intervention: McDavid 199 Lightweight ankle brace
Number of subjects: 20

Group type: COMPARATOR
Intervention: No ankle brace
Number of subjects: 20
Study: 19948946

Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 400 mg nilotinib
Number of subjects: 21

Group type: COMPARATOR
Intervention: Water with 400 mg nilotinib
Number of subjects: 21
Study: 18603410

Group type: EXPERIMENTAL
Intervention: Compression with ice (Group A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Compression without ice (Group B)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No compression (Group C)
Number of subjects: 95
Study: 15819283

Group type: EXPERIMENTAL
Intervention: Etoricoxib, 30 mg once daily
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 800 mg 3 times daily
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 12729814

Group type: EXPERIMENTAL
Intervention: In-vehicle phone distraction task
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition (no phone distraction)
Number of subjects: 42
Study: 10589361

Group type: EXPERIMENTAL
Intervention: Etanercept-MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-MTX
Number of subjects: 0
Study: 8699272

Group type: EXPERIMENTAL
Intervention: Videotape
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Instructional booklet
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lecture
Number of subjects: 150
Study: 1862063

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration chart
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no chart)
Number of subjects: 30
Study: 6419596

Group type: EXPERIMENTAL
Intervention: Auranofin (6 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: D-penicillamine (500 mg per day)
Number of subjects: 40
Study: 30709557

Group type: EXPERIMENTAL
Intervention: Combined aprepitant therapy (aprepitant plus dexamethasone and tropisetron)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (dexamethasone and tropisetron)
Number of subjects: 100
Study: 29057429

Group type: EXPERIMENTAL
Intervention: Open-label suggestions
Number of subjects: 92

Group type: COMPARATOR
Intervention: No suggestions (Control)
Number of subjects: 92
Study: 26921267

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) as an add-on to treatment as usual (TAU)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Psychoeducational programme (FibroQoL) as an add-on to treatment as usual (TAU)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 180
Study: 24521531

Group type: EXPERIMENTAL
Intervention: Universal family and school program (EBPIs) offered to families in 6th grade and one of three school-based programs in 7th grade.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-based programs used in conjunction with school-based programs.
Number of subjects: 0
Study: 22127729

Group type: EXPERIMENTAL
Intervention: Alendronate treatment group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 52
Study: 21406947

Group type: EXPERIMENTAL
Intervention: Couple dissatisfaction (34.8%)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Distraction-oriented coping style
Number of subjects: 65
Study: 17370037

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 over 1 h on day 1 followed by ifosfamide 5 g/m2 divided over days 1 and 2 (2.5 g/m2/day over 1 h), recycled every 21 days with prophylactic G-CSF administration from day 3 until a neutrophil count >10,000/microl.
Number of subjects: 71
Study: 16011127

Group type: EXPERIMENTAL
Intervention: FloSeal (FS) packing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thrombin-soaked gelatin foam
Number of subjects: 18
Study: 12177583

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/day
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Ziprasidone (all doses)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 278
Study: 9539583

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 44
Study: 8586834

Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day orally) with exogenous angiotensin II (1 ng/kg per min intravenously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day orally) with frusemide (40 mg/day orally for 2 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporin (10 mg/kg twice a day orally)
Number of subjects: 0
Study: 2710909

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (N = 30)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Biofeedback (N = 27)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (no treatment, N = 20)
Number of subjects: 77
Study: 902626

Group type: EXPERIMENTAL
Intervention: Propranolol and hydroflumethiazide (HFM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Propranolol and HFM
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study: 31282392

Group type: EXPERIMENTAL
Intervention: Femoral nerve mobilization (FNM)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sciatic nerve mobilization (SNM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 68